ConductScience.org, home
CRBN: cereblon
API referenceFor AI assistants

Gene · 51185

Papers2,935

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

1 to 20 of 2,935

Download this page as JSON
TitleJournalYearPMIDFound bySource
PROTAC probe-assisted degradomics identifies SPINT2 as a candidate cellular target involved in the anti-cancer activity of Flupentixol.Bioorg Chem202642826660PubTator, text miningPubMed
A scalable, high-throughput glue perturbation screening platform for molecular glue discovery.iScience202642824958PubTator, text miningPubMed
Beyond Immunomodulatory Drugs: Next-Generation Cereblon Modulators in Multiple Myeloma.Cancer J202642809693PubTator, text miningPubMed
Optimizing CRBN-ligands for optical targeted protein degradation.RSC Med Chem202642807851PubTator, text miningPubMed
Bridging E3 Ligase Binding and Targeted Degradation Through Fluorescence Polarization.Int J Mol Sci202642794484PubTator, text miningPubMed
Design, synthesis and biological evaluation of a series of new, potent FLT3 PROTAC degraders with rigid linkers.Bioorg Med Chem202642772077PubTator, text miningPubMed
Molecular glues: Recent advances in cereblon substrate identification and mechanistic insights.Smart Mol202642770064PubTator, text miningPubMed
PARP1-targeting PROTAC attenuates alcohol-associated liver injury and ileal epithelial damage.Biochem Pharmacol202642753829PubTator, text miningPubMed
Design, Synthesis, Biological Studies and Putative Binding Mode of Novel Benzotriazolothalidomide Derivatives as Cereblon Ligands.Chem Biol Drug Des202642740472PubTator, text miningPubMed
Expanding the E3 Ligase Landscape: From Small Molecule to Biological Targeted Protein Degradation.Handb Exp Pharmacol202642730806PubTator, text miningPubMed
Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in Multiple Myeloma: 30 Years in the Making.J Clin Oncol202642721415PubTator, text miningPubMed
TRI-611, a selective, brain-penetrant molecular glue degrader of ALK.Nature202642717093PubTator, text miningPubMed
Discovery of highly potent and efficacious Bromodomain and Extra-terminal (BET) degraders with activity against acute myeloid leukemia and triple-negative breast cancer.Eur J Med Chem202642715871PubTator, text miningPubMed
Beyond random splits: A hierarchical benchmark of transferability and reliability in PROTAC activity prediction.Comput Biol Chem202642691622PubTator, text miningPubMed
Discovery of BMS-986449: A Potent, Selective Degrader of the Transcription Factors IKZF2 (Helios) and IKZF4 (Eos) to Target Regulatory T Cells in Solid Tumors.J Med Chem202642677819PubTator, text miningPubMed
Non-genetic remodeling drives leukemia propagation and reveals actionable vulnerabilities in acute myeloid leukemia.Cell Rep Med202642673946PubTator, text miningPubMed
Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation.Adv Sci (Weinh)202642669594PubTator, text miningPubMed
EZH2-dependent STAT3 stabilization drives pomalidomide resistance and is targetable by EZH2 inhibition in multiple myeloma.Acta Biochim Biophys Sin (Shanghai)202642647107PubTator, text miningPubMed
Direct phospho-proteoform delivery reveals a degradation-prone monomeric state of 14-3-3.Chem Sci202642630645PubTator, text miningPubMed
Discovery of rigid linker-based CDK4/6 PROTACs for the treatment of breast cancer.Bioorg Chem202642628378PubTator, text miningPubMed

gene-search-2026-11-11-0.2.0

Next page

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/genes/v1/51185/papers

API referenceFor AI assistants